Amid swirling speculation, Bausch + Lomb ($BLCO), a global leader in the contact lens supply industry, is reportedly ...

It isn't known whether Bausch + Lomb and/or Goldman is in contact with either Blackstone or TPG. According to the FT, several private equity funds mulling offers have dropped out of the race.

including Biotrue and SofLens. We are still impressed at the overall performance and believe the firm's share in the contact lens market slightly increased. Miebo and Xiidra, Bausch & Lomb's dry ...

H.C. Wainwright analyst Yi Chen reiterated a Buy rating on Bausch + Lomb Corporation (BLCO – Research Report) today and set a price ...

Bausch + Lomb shares surged Monday following reports Blackstone and TPG are considering teaming up to buy the eyecare company. A bid from Blackstone and TPG could reportedly value the company ...

Wells Fargo analyst Larry Biegelsen raised the firm’s price target on Bausch + Lomb (BLCO) to $26 from $23 and keeps an Overweight rating ...

VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, will release its third ...

Bausch & Lomb (NYSE:BLCO) jumped 7.5% on a report that private equity firms TPG (TPG) and Blackstone (BX) are working on a joint bid for the eyecare company. Several other PE shops that have been ...

Bausch + Lomb scaled up its revenue guidance for the year after swinging to a profit in the latest quarter on the back of sales growth in each of its business segments.

Continued progress on the buyout of Bausch & Lomb is lifting shares, with the stock up over 6% at the time of writing. Financial Times reported on Oct. 14 that two prominent figures involved in ...

Monday was an eventful day for Bausch + Lomb (NYSE: BLCO). The eye care specialist's major piece of internal news was that it earned its latest Food and Drug Administration (FDA) approval.